Disgusting for a public company. Appears to be no consensus view on how to move this drug forward and management infighting has caused delays and irreparable damage to the company and its prospects.
while a prefer a management team with skin in the game there are plenty of examples where this a problem and they can’t see the forest through the trees.
get on with it I say, I’d expect DT to at least explain what the issues were with DCB and the new strategy. Hard to see how he isn’t behind these changes.
Disgusting for a public company. Appears to be no consensus view...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 176 | $1.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 8182 | 2 |
View Market Depth
| Last trade - 08.33am 03/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |
Day chart unavailable